survey development, data collection, and analyses  (CSL Behring)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D RNA-Seq-based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: Marker, RNA Sequencing, Expressing, Derivative Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Identifying the optimal humanized bone marrow mouse type for the humanized immune stroma PDX (HIS-PDX). PDX models established in immunodeficient NSG, humanized HuNSG-SGM3 and humanized BLT mice were named as NSG-PDX, HuSGM3-PDX and BLT-PDX models, respectively. A-C RNA-seq-based mRNA analysis of the indicated lymphocyte ( A ), myeloid cell ( B ) and NK cell ( C ) markers genes in NSG-PDX, HuSGM3-PDX and BLT-PDX tumors. Expression is normalized using the expression in matched primary patient-derived tumor. D IF for human CD3, CD8, CD14 and CD163 evaluating tumor immune infiltrates in the indicated PDX tumor models. Cell nuclei were counterstained with DAPI (blue). Scale bars, 20 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: RNA Sequencing, Expressing, Derivative Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Analysis of complete humanized immune stroma PDX (HIS-PDX). HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). A IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei were counterstained with DAPI (blue) ( n = 3). B Hematoxylin and eosin (H&E) staining for a cell line-derived xenograft, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor ( n = 3). C RNA-seq derived heat map for stromal and immune gene expression in solid tumor-derived standard PDXs (StndPDX), HIS-PDX and patient primary tumor ( n = 3). D Total gene expression correlation between primary human tumor and primary tumor-derived HIS-PDX for patient 1 and patient 4. Scale bars in ( A ), 40 µm; scale bars in ( B ), 100 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: Staining, Derivative Assay, RNA Sequencing, Gene Expression